Wise · 2016 · PloS one
Trial of cellular defenses and lung function in COPD
Would the cellular defense response observed in healthy people also appear in patients with chronic obstructive pulmonary disease?
Human · randomized double-blind controlled trial
Key findings
Four-week assessment of cellular defenses and lung function
In a trial of 89 patients with chronic obstructive pulmonary disease, no significant between-group differences were found in NRF2 target genes, inflammation, oxidative stress, or lung function markers.
Study design
Eighty-nine patients with COPD were divided into three groups: placebo, SFN 25μmol/day, and SFN 150μmol/day, for a four-week comparison. NRF2 target genes in bronchial and blood samples, inflammation, and lung function were evaluated.
- Participants
- 89 patients with chronic obstructive pulmonary disease
double-blind randomized trial - Intake and observation
- Sulforaphane 25 or 150μmol/day
4 weeks · placebo controlled - Measures
- NRF2 target genes · lung function
Study context
Cells collected from the bronchi and blood were analyzed. This trial compared sulforaphane doses of 25μmol and 150μmol with placebo.
Original paper and sources
Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial.
- Journal
- PloS one · 2016 · 11(11): e0163716
- First published
- 2016-11-10
2017 correction notice · Funding information for one author was added.